title: UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy.
abstract: OBJECTIVE
  Urothelial carcinoma associated 1 (UCA1) functions as an oncogene, which promotes cancer cell proliferation, invasion, and metastasis, and is responsible for drug resistance. This study aimed to determine the expression level of UCA1 in ovarian cancer and to further investigate its clinical significance.
  
  
  METHODS
  The expression levels of UCA1 in ovarian cancer and normal ovaries were determined by quantitative real-time PCR. The relationship between UCA1 expression and clinical features and the prognostic value of UCA1 for overall survival were examined.
  
  
  RESULTS
  UCA1 expression in ovarian cancer tissues was significantly upregulated compared with normal ovarian tissues. High UCA1 expression was related to lymph node metastasis, FIGO stage, and response to chemotherapy. Kaplan-Meier analysis demonstrated that high UCA1 expression was associated with poorer overall survival in patients with ovarian cancer. Cox proportional hazards analysis showed that high UCA1 expression was an independent prognostic marker of poor outcome. This effect remained significant in the further stratification analysis.
  
  
  CONCLUSIONS
  Our findings provided the first evidence that UCA1 may serve as an indicator of response to chemotherapy and prognosis of ovarian cancer. UCA1 may play an important role in the progression of ovarian cancer.
authors: Department of Obstetrics and Gynecology, Taizhou Central Hospital, Taizhou, Zhejiang, China.
authors: Ling
authors: L
authors: Zhang
authors: Department of Medical Equipment, Taizhou Central Hospital, Taizhou, Zhejiang, China.
authors: Xili
authors: X
authors: Cao
authors: Department of Obstetrics and Gynecology, Taizhou Central Hospital, Taizhou, Zhejiang, China.
authors: Liqian
authors: L
authors: Zhang
authors: Department of Thoracic Surgery, Taizhou Central Hospital, Taizhou, Zhejiang, China.
authors: Xuelin
authors: X
authors: Zhang
authors: National Engineering Center for Biochip at Shanghai, Shanghai, China. haihui_sheng@shbiochip.com.
authors: Haihui
authors: H
authors: Sheng
authors: Department of Pathology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. taokun20119@163.com.
authors: Kun
authors: K
authors: Tao
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D062085:RNA, Long Noncoding / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D015854:Up-Regulation / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D062085:RNA, Long Noncoding; C515159:UCA1 RNA, human
keywords: Long noncoding RNA; Ovarian cancer; Overall survival; Urothelial carcinoma associated 1